HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Are clinically insignificant prostate cancers really insignificant among Korean men?

AbstractPURPOSE:
We aimed to determine whether 12 core-extended biopsies of the prostate could predict insignificant prostate cancer (IPCa) in Koreans reliably enough to recommend active surveillance.
MATERIALS AND METHODS:
Two hundred and ninety-seven patients who underwent radical prostatectomy after 12 core-extended prostate biopsies were retrospectively reviewed. 38 cases (12.8%) were shown to be IPCa.
RESULTS:
The average age was 65.2 years, serum PSA was 5.49 ng/dL, and the PSA density was 0.11. The Gleason scores (GS) were 6 (3+3) in 31, 5 (3+2) in 4, and 4 (2+2) in 3. After radical prostatectomy, higher GS was given in 16 (42.1%), whereas lower GS was given in 1 case (2.6%), as compared with the GS obtained from biopsy. 11 (28.9%) had GS of 7 (3+4) and 5 (13.2%) had GS of 7 (4+3). 6 in GS 7 (4+3) and 1 in GS 7 (3+4) showed prostate capsule invasion and 1 in GS 7 (4+3) had seminal vesicle invasion. Prostate capsule invasion was observed in 1 with GS 6 (3+3). The rate of inaccuracy of the contemporary Epstein criteria was 42.1%. Only PSA density was a reliable indicator of clinically IPCa (odds ratio=1.384, 95% CI, 1.103 to 2.091).
CONCLUSION:
Diagnosis of IPCa from a prostate biopsy underestimated the true nature of prostate cancer in as many as 42.1% of Koreans.
AuthorsChan Dong Yeom, Seung Hwan Lee, Kyung Kgi Park, Sang Un Park, Byung Ha Chung
JournalYonsei medical journal (Yonsei Med J) Vol. 53 Issue 2 Pg. 358-62 (Mar 2012) ISSN: 1976-2437 [Electronic] Korea (South)
PMID22318824 (Publication Type: Journal Article)
Chemical References
  • Prostate-Specific Antigen
Topics
  • Aged
  • Humans
  • Male
  • Middle Aged
  • Prostate-Specific Antigen (blood)
  • Prostatectomy
  • Prostatic Neoplasms (blood, diagnosis, surgery)
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: